Details for Patent: 7,632,870

Which drugs does patent 7,632,870 protect, and when does it expire?

Patent 7,632,870 protects IQIRVO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Recent additions to Drugs Protected by US Patent 7,632,870

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Ipsen	IQIRVO	elafibranor	TABLET	218860	Jun 10, 2024	RX	Yes	7,632,870	Y

Drugs Protected by US Patent 7,632,870

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	IQIRVO	elafibranor	TABLET;ORAL	218860-001	Jun 10, 2024		RX	Yes	Yes	7,632,870		Y

International Family Members for US Patent 7,632,870

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E364588
Australia	2003264699
Brazil	0312399